Red shell: defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy.

PURPOSE To define a volume of tissue just outside of the clinical target volume (CTV) or planning target volume (PTV) in stereotactic body radiation therapy (SBRT) that receives doses appreciably above the tolerance level and in which other critical tissue structures must be avoided. METHODS AND MATERIALS We define the tissue between the borders of the CTV and PTV as the Inner Red Shell. The tissue surrounding the PTV that receives higher than the local tissue tolerance is defined as the Outer Red Shell. Contributing factors to the volume of the Red Shell include the prescription dose, dose gradient and PTV size, together with the type of tissue and its tolerance are discussed. An illustrative example and two clinical cases are reported. RESULTS The volume of Red Shell increases with higher prescription dose, slower dose fall-off, larger PTV volume, and higher tissue radiosensitivity. Avoidance of proximal critical serial organs may alter the volume and shape of the Red Shell after repeated, detailed treatment planning. CONCLUSION Rather than defining tolerance and toxicity as simply a dose level received by the tissues, the volume of tissue receiving risk levels above tolerance can be quantified as the "cost" of SBRT. This concept may be adopted in other techniques offering ablative and high-dose gradients. Further consideration should be given to collecting clinical data for refining the choice of constraint doses, especially in parts of the brain, lung, liver, and kidney.

[1]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[2]  J. Fowler Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008;70:847-852). , 2008, International journal of radiation oncology, biology, physics.

[3]  A. Nahum,et al.  Early mucosal reactions during and after head-and-neck radiotherapy: dependence of treatment tolerance on radiation dose and schedule duration. , 2008, International journal of radiation oncology, biology, physics.

[4]  Srinivasan Vijayakumar,et al.  Technical Basis of Radiation Therapy , 2006 .

[5]  H. Bartelink,et al.  Fractionation in radiotherapy. , 1994, Cancer treatment reviews.

[6]  J F Fowler,et al.  Optimum overall times II: Extended modelling for head and neck radiotherapy. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  J. Fowler,et al.  Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  M. Hoogeman,et al.  Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. , 2009, International journal of radiation oncology, biology, physics.

[9]  J. Fowler Comment on "Magical protons?" editorial by Goitein (Int J Radiat Oncol Biol Phys 2008;70:654-656). , 2008, International journal of radiation oncology, biology, physics.

[10]  R. Timmerman,et al.  Stereotactic Body Radiation Therapy: A Comprehensive Review , 2007, American journal of clinical oncology.

[11]  Robert D Timmerman,et al.  A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. , 2005, International journal of radiation oncology, biology, physics.